

**MEDICINE
PROBLEMS**

.uz

ISSN 3030-3133

**TIBBIYOT FANLARINING
DOLZARB MASALALARI**

**TOPICAL ISSUES OF MEDICAL
SCIENCES**



**Nº 2 (3)
2025**



САЙТ: <https://medicineproblems.uz>
ISSN: 3030-3133

MEDICINEPROBLEMS.UZ
TIBBIYOT FANLARINING DOLZARB
MASALALARI
№ 2 (3)-2025

TOPICAL ISSUES OF MEDICAL SCIENCES

TOSHKENT-2025

BOSH MUHARRIR:

ISANOVA SHOIRA TULQINOVNA- Tibbiyot fanlari bo'yicha falsafa doktori (PhD), Samarqand davlat tibbiyot universiteti

TAHRIR HAY'ATI:

TIBBIYOT FANLARI

Safarov Zafar Fayzullayevich –tibbiyot fanlari bo'yicha falsafa doktori (PhD), Toshkent pediatriya tibbiyot instituti;

Xakimov Murod Shavkatovich –tibbiyot fanlari doktori, professor, Toshkent tibbiyot akademiyasi;

Mavlanov Alimbay – tibbiyot fanlari doktori, professor, Toshkent tibbiyot akademiyasi;

Ergashev Nasriddin Shamsiddinovich - tibbiyot fanlari doktori, professor, Toshkent pediatriya instituti;

Abdullayeva Nargiza Nurmamatovna - tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti;

Djurabekova Aziza Taxirovna - tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti;

Xaydarova Dildora Kadirovna - tibbiyot fanlari doktori, professor, Toshkent tibbiyot akademiyasi;

Ruziboyev Sanjar Abdusalomovich- tibbiyot fanlari doktori, dotsent, Samarqand davlat tibbiyot universiteti;

Sattarov Oybek Toxirovich- tibbiyot fanlari doktori, dotsent, Toshkent tibbiyot akademiyasi;

Niyozov Shuxrat Tashmirovich - tibbiyot fanlari doktori, dotsent, Samarqand davlat tibbiyot universiteti;

Tavasharov Bahodir Nazarovich – tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

Xalmetova Feruza Iskandarovna – tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

G'aybiyev Akmaljon Axmadjonovich - tibbiyot fanlari bo'yicha falsafa doktori (PhD), dotsent, Samarqand davlat tibbiyot universiteti;

Qo'ziyev Otabek Juraqulovich – tibbiyot fanlari nomzodi, dotsent, Toshkent pediatriya tibbiyot instituti;

Ergasheva Munisa Yakubovna - tibbiyot fanlari bo'yicha falsafa doktori (PhD), dotsent, Samarqand davlat tibbiyot universiteti;

Ollanova Shaxnoza Sirlibayevna – tibbiyot fanlari nomzodi, Samarqand davlat tibbiyot universiteti;

Safarov Zafar Fayzullayevich – tibbiyot fanlari nomzodi, Toshkent pediatriya tibbiyot instituti;

Xayitov Ilxom Bahodirovich – tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

Alimov Suxrob Usmonovich- tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

Fozilov Uktam Abdurazzokovich - tibbiyot fanlari nomzodi, dotsent, Buxoro davlat tibbiyot instituti;

Raximov Oybek Umarovich – tibbiyot fanlari nomzodi, Toshkent pediatriya instituti;

Sattarov Inayat Saparbayevich – tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

Abidov O'tkir O'ktamovich – tibbiyot fanlari nomzodi, Buxoro davlat tibbiyot instituti;

Amonova Zaxro Qaxramon qizi - tibbiyot fanlari nomzodi, Samarqand davlat tibbiyot universiteti.

FARMATSEVTIKA FANLARI

Zulfikariyeva Dilnoza Alisherovna - farmatsevtika fanlari doktori (DSc), professor, Toshkent farmatsevtika instituti;

Toshpo'latova Azizaxon Dilshodovna - farmatsevtika fanlari doktori (DSc), professor, Toshkent farmatsevtika instituti;

Xusainova Rayxona Ashrafovna - farmatsevtika fanlari doktori (DSc), dotsent, Toshkent farmatsevtika instituti;

Maksudova Firuza Xurshidovna farmatsevtika fanlari doktori (DSc), dotsent, Toshkent farmatsevtika instituti;

Ziyamuxamedova Munojot Mirgiyasovna - farmatsevtika fanlari doktori, Toshkent farmatsevtika instituti, dotsent v.b.;

Rizayeva Nilufar Muxutdinovna – farmatsevtika fanlari nomzodi, dotsent Toshkent farmatsevtika instituti;

TIBBIYOT FANLARINING DOLZARB

MASALALARI elektron jurnali 02.03.2023-yilda 132099-sonli guvohnoma bilan davlat ro'yxatidan o'tkazilgan.

Muassis: "SCIENCEPROBLEMS TEAM" mas'uliyati cheklangan jamiyati.

TAHRIRIYAT MANZILI:

Toshkent shahri, Yakkasaroy tumani, Kichik Beshyog'och ko'chasi, 70/10-uy. Elektron manzil: scienceproblems.uz@gmail.com

Telegram kanal:

https://t.me/Scienceproblemsteam_uz

MUNDARIJA

<i>An Andrey Vladimirovich, Bekbauliyeva Gulistan Niyetbayevna, Kamolova Marjona Asilbekovna</i> INFEKSION VA YALLIG'LANISH GENEZLI PLATSENTA DISFUNKSIYASI MUAMMOSINING HOZIRGI ASPEKTLARI	7-18
<i>Турсунова Лайло Дилшатовна, Жаббаров Озимбай Отаханович</i> ДИАГНОСТИЧЕСКОЕ И ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ β 2-МИКРОГЛОБУЛИНА ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК	19-25
<i>Bektemirova Begoyim Baxtiyorjon qizi</i> REPRODUKTIV FAOLIYATDA QIN MIKROBIOMINING AHAMIYATI	26-33

CONTENT

<i>An Andrey Vladimirovich, Bekbauliyeva Gulistan Niyetbayevna, Kamolova Marjona Asilbekovna</i>	
CURRENT ASPECTS OF THE PROBLEM OF PLACENTAL DYSFUNCTION AND MISCARRIAGE OF INFECTIOUS AND INFLAMMATORY GENESIS	7-18
<i>Tursunova Laylo Dilshatovna, Jabbarov Ozimbay Otaxanovich</i>	
DIAGNOSTIC AND PROGNOSTIC VALUE OF β 2-MICROGLOBULIN IN CHRONIC KIDNEY DISEASE	19-25
<i>Bektemirova Begoyim Baxtiyorjon qizi</i>	
IMPORTANCE OF VAGINAL MICROBIOME IN REPRODUCTION	26-33

Received: 1 April 2025
Accepted: 15 April 2025
Published: 10 May 2025

Article / Original Paper

CURRENT ASPECTS OF THE PROBLEM OF PLACENTAL DYSFUNCTION AND MISCARRIAGE OF INFECTIOUS AND INFLAMMATORY GENESIS

An Andrey Vladimirovich

Associate professor

Bekbauliyeva Gulistan Niyetbayevna

Associate professor

Kamolova Marjona Asilbekovna

Master's student

Tashkent Medical Academy, Uzbekistan

Abstract. Placental dysfunction and miscarriage of infectious and inflammatory origin remain urgent problems in modern obstetrics, significantly contributing to perinatal morbidity and mortality. This article reviews the etiopathogenetic mechanisms of placental insufficiency, emphasizing the role of viral and bacterial infections, immune responses, and systemic inflammatory reactions. Special attention is given to ozone therapy as a promising complementary approach in treating such conditions. The biological effects of ozone—antibacterial, anti-inflammatory, antioxidant, and immunomodulatory—are discussed as potential tools to improve maternal and fetal outcomes in high-risk pregnancies.

Key words: placental dysfunction, miscarriage, inflammation, infection, ozone therapy, perinatal complications, obstetrics.

INFEKSION VA YALLIG'LANISH GENEZLI PLATSENTA DISFUNKSIYASI MUAMMOSINING HOZIRGI ASPEKTLARI

An Andrey Vladimirovich

T.f.n. dotsent

E-mail: andrey.an.vl@mail

Bekbauliyeva Gulistan Niyetbayevna

T.f.d. dotsent

E-mail: gulistanb2006@yahoo.com

Kamolova Marjona Asilbekovna

Talaba-magistr

Toshkent tibbiyot akademiyasi

Annotatsiya. Platsentaning disfunktsiyasi zamonaviy akusherlikning dolzarb muammolari bo'lib qolmoqda, bu perinatal kasallik va o'limga sezilarli hissa qo'shadi. Ushbu maqolada platsenta yetishmovchiligining etiopatogenetik mexanizmlari ko'rib chiqiladi, virusli va bakterial infeksiyalar, immunitet reaksiyalari va tizimli yallig'lanish reaksiyalarining rolini ta'kidlaydi. Bunday sharoitlarni davolashda istiqbolli qo'shimcha yondashuv sifatida ozon terapiyasiga alohida e'tibor beriladi. Ozonning biologik ta'siri — antibakterial, yallig'lanishga qarshi, antioksidant va immunomodulator — yuqori xavfli homiladorlikda ona va homila natijalarini yaxshilash uchun potensial vositalar sifatida muhokama qilinadi.

Kalit so'zlar: platsenta disfunktsiyasi, abort, yallig'lanish, infeksiya, ozon terapiyasi, perinatal asoratlari, akusherlik.

DOI: <https://doi.org/10.47390/3030-3133V3I2Y2025N01>

One of the most significant problems of modern obstetric practice remains miscarriage (MP) [36,46]. This term refers to spontaneous termination of pregnancy at any stage – from the moment of conception to 37 weeks, which corresponds to the period from the first day of the last menstrual period to the 259th day. [55]

According to WHO, premature birth is considered to be a birth that occurs between 22 and 37 completed weeks of gestation, counted from the first day of the last menstrual period, with a fetal weight of 500 g or more. [46,55]

Miscarriage occurs in 10-25% of all pregnancies, with 5-10% ending in premature birth. More than half of stillbirths occur in premature babies, who also account for 70-80% of early neonatal mortality and 60-70% of infant mortality. The probability of death of a premature baby is 30-35 times higher than that of a full-term baby, and the perinatal mortality rate in miscarriage exceeds the same indicator for term births by 30-40 times. [55] In recent years, the proportion of premature births in Uzbekistan has ranged from 9 to 15%, with about 70% of early neonatal mortality cases due to prematurity. [34]

These data confirm that the problem of miscarriage remains relevant for modern medicine.

When treating miscarriage, specialists are faced with a limited number of attempts, which places great responsibility on the doctor when conducting diagnostics and choosing the optimal treatment tactics. It is important to consider that each lost pregnancy not only becomes a serious psychological trauma for a woman, but also negatively affects her reproductive health. This is due to both the consequences of the termination of pregnancy itself and the need for invasive interventions. Thus, each unsuccessful pregnancy intensifies the pathological processes that contribute to miscarriage, which further complicates its treatment. Termination of pregnancy after 16 weeks is usually caused by pathological processes such as infections, isthmic-cervical insufficiency and thrombophilic disorders. These factors provoke the development of placental insufficiency and severe pregnancy complications, including placental abruption, intrauterine growth retardation, gestosis and other complications [36].

It has been proven that one of the main causes of early premature birth is local inflammation of the chorion and decidua in the cervix. In most cases, it is associated with the persistence of opportunistic mycoplasma-viral microflora in the endometrium. [44]

The results of a number of studies have shown that the cause of pregnancy termination can be both severe systemic inflammatory diseases and asymptomatic urogenital infections. [27]. Risk factors for the development of infectious diseases in pregnant women and the fetus can be divided into three main groups (31,32). The first group includes women with chronic foci of extragenital infection, among which are: long-term nonspecific diseases of the respiratory system, chronic inflammatory processes in the gastrointestinal tract, chronic tonsillitis, chronic pyelonephritis. The second group includes pregnant women with chronic inflammatory diseases of the reproductive system, which include: colpitis, lower genital tract infections, endometritis, salpingo-oophoritis. The third group includes patients who experienced an exacerbation of chronic infectious diseases during pregnancy, as well as those who suffered acute inflammatory processes during the gestational period (57).

In recent decades, the need to find and justify new or additional methods of therapy has become especially urgent due to the increase in morbidity, the emergence of microorganism

resistance to existing drugs, and the development of new forms of diseases. Modern medicine faces challenges related to the limited effectiveness of traditional treatment methods, side effects, and their insufficient universality for different groups of patients.

The importance of finding and implementing new methods of therapy is also reinforced by the need to adapt medicine to changes in population health and the rapid progress of scientific technologies.

The purpose of this literature review is to analyze existing approaches to the treatment of placental dysfunction and miscarriage caused by infectious and inflammatory factors, as well as to determine the place of ozone therapy among alternative and traditional treatment methods. The review examines the effectiveness of various therapeutic strategies aimed at correcting infectious and inflammatory processes and improving placental functioning, with a special emphasis on the possibility of using ozone therapy. Based on the systematization of available data on the effectiveness and safety of various therapeutic strategies, it is proposed to substantiate the prospects of further studies aimed at clarifying the mechanism of action and expanding the indications for the use of ozone therapy in obstetric practice.

Etiopathogenetic mechanisms of formation of placental dysfunction in women with infectious and inflammatory diseases of the reproductive system.

Placental dysfunction is a complication of pregnancy that is accompanied by intrauterine fetal distress, growth retardation and developmental delay, and is also one of the significant factors of perinatal morbidity and mortality [5, 64]. This syndrome is characterized by morphofunctional changes in the placenta and is a consequence of a complex adaptive response of the fetoplacental complex to various pathological processes in the mother's body. Its development is based on a violation of compensatory-adaptive mechanisms at the molecular, cellular and tissue levels [19, 62]. As a result, the main functions of the placenta are impaired - transport, trophic, endocrine, metabolic and detoxification, which negatively affects the condition of the fetus and newborn. Placental dysfunction accompanies almost all complicated forms of pregnancy. In patients suffering from viral and bacterial infections, its frequency reaches 50.0% - 60.0%. The morphological basis of this condition is pronounced changes in the vascular network of the placenta, including narrowing and tortuosity of the spiral arterioles, their heterogeneity in caliber, a decrease in the density of the arterial bed, as well as a decrease in the lumen of the capillaries with foci of stasis, aggregation and adhesion of cellular elements of the blood [2, 7].

According to T. S. Kachalina and co-authors [26], massive fibrin deposits in the intervillous space, pronounced edema and fibrosis of the chorionic villi are detected in the placental tissue, which is caused by primary vascular disorders. At the same time, J. Aplin [3] proved the possibility of secondary changes in the placental vessels, which arise due to thinning of the walls of large vessels, which leads to a decrease in the volume and area of terminal villi during placentation.

There are two main types of placental dysfunction (PD): primary (early) and secondary (late). Primary placental insufficiency develops before 16 weeks of gestation, during implantation, early embryogenesis and placenta formation. Its occurrence is associated with the influence of genetic, endocrine, infectious and other unfavorable factors. The ability of the mother's body to adapt to pregnancy also plays an important role. Quite often, primary PD is accompanied by congenital malformations of the fetus. Secondary (late) placental insufficiency

develops after the 16th week of gestation, when the placenta has already formed, and is caused by exogenous blood supply disorders, as well as dystrophic and inflammatory processes that occur as a result of diseases suffered during pregnancy. The degree of influence of various pathological conditions and diseases of the pregnant woman on the condition of the placenta and fetus is determined not only by the gestational age and duration of exposure, but also by the capabilities of the compensatory-adaptive mechanisms of the fetoplacental complex (FPC) [49, 64]. If the compensatory functions of the placenta are preserved, its insufficiency can be treated, which allows for the normal development of the fetus to be maintained and the pregnancy to be carried to term with the subsequent birth of a healthy child. However, if the adaptive mechanisms are exhausted, the risk of intrauterine growth retardation of the fetus and serious complications increases [1, 33].

The development of placental dysfunction (PD) is caused by the impact of many risk factors, among which the key role is played by late gestosis, the threat of termination of pregnancy, postmaturity, iso-serological incompatibility, as well as somatic diseases of the mother, such as pathologies of the cardiovascular system and kidneys. TORCH group infections are also of significant importance [26, 8].

In addition, predisposing factors for the development of PD are unfavorable socio-economic conditions, low level of education, young age (under 17 years), especially with insufficient body weight before pregnancy and its insufficient increase in the gestational period. Inadequate physical activity, first birth and multiple pregnancy also increase the risk of developing this pathology.

In recent years, the role of TORCH infections in the mechanisms of placental insufficiency development has been actively discussed in scientific research [11]. In particular, the influence of herpes viruses and cytomegalovirus on the formation of PD is confirmed by the high degree of relationship between these infections and placental dysfunction, reaching 92.2%.

Placental dysfunction is one of the leading factors influencing the level of perinatal morbidity and mortality. Despite numerous scientific studies devoted to fetoplacental insufficiency, manifested as intrauterine growth retardation syndrome, all damaging perinatal factors that determine the pathological development of children in the early neonatal period and during the first year of life have not yet been identified [16, 17].

The presence of a significant number of concomitant genital and somatic diseases in the mother creates an unfavorable pregravid background, which contributes to an additional load on the key life support systems. In the early stages of pregnancy, due to the high adaptive capacity of the "mother-placenta-fetus" system, these changes can remain in a compensated state or be accompanied by moderate disturbances in the hormonal regulation of the fetoplacental complex.

Infectious and inflammatory diseases are diagnosed in 28.0%–47.0% of newborns, and in the structure of perinatal losses they make up from 11.0% to 45.0%. Intrauterine infections have a significant negative impact on the perinatal outcome of pregnancy, which necessitates a comprehensive study of this problem in modern scientific research [18].

An analysis of the characteristics of the course of pregnancy and childbirth in women, in a group of which pregnant women with infectious diseases and chronic placental insufficiency complicated by an unfavorable outcome of childbirth were identified, revealed a significant proportion of premature newborns (33.8%) and children with signs of hypotrophy (35.2%). In

addition, among this category of patients, a high level of intrauterine infection of the fetus was recorded, reaching 40.8%, which indicates a significant influence of the infectious factor on the perinatal prognosis. [25].

Many scientists emphasize the significant role of urogenital infections suffered in the first trimester in the development of miscarriage [56,58]. Thus, studies by A.V. Grishchenko and co-authors [22] showed that inflammatory diseases of the reproductive system in the anamnesis occur in 40.2%–51.0% of women who have encountered this pathology.

Persistent viral infections and their combined forms [51], which are detected in 74.0% of patients [43], acquire special etiological significance in miscarriage. In the early stages of gestation, infectious agents have the most pronounced negative impact on the development of the embryo.

Even opportunistic vaginal microflora, which may be asymptomatic in the mother, can provoke intrauterine infection of the fetus and the development of an infectious process.

Cytomegalovirus infection (CMV) is recognized as one of the most common intrauterine infections. According to statistics, about 1.0% of newborns are infected with CMV, but only 10.0% of them have clinical manifestations at birth confirming intrauterine infection.

Natural origin, physical and chemical properties and medical and biological effects of medical ozone.

Ozone was first reported by the Dutch physicist Mac van Marum in 1785, during experiments with a powerful installation for electrification, he observed how, when passing an electric spark through the air, a gaseous substance with a peculiar smell and strong oxidizing properties appeared. In 1801, Krunschken discovered a similar smell during the electrolysis of water, and in 1840, Professor K. F. Schonbein of the University of Basel associated these changes in the properties of oxygen with the formation of a special gas, which he named ozone (from the Greek word "smell"). A hundred years later, Hansler created the first medical ozone generator, which expanded the boundaries of its use, thanks to the ability to accurately dose the ozone-oxygen mixture. [66]

It is known that ozone is formed in all processes accompanied by the appearance of atomic oxygen. In laboratory conditions and industry, ozone is obtained in ozonizers by the action of an electric discharge on oxygen. The main types of industrial ozonizers have a flat or tubular discharge chamber, glass or ceramics are used as a dielectric, and the electrodes are made of aluminum or copper. The power of the ozonizer is proportional to the frequency of the current.

The main physical characteristics of ozone have been studied in detail and described by S.D. Razumovsky and G.E. Zaykov [47]. Ozone (O₃) is an allotropic modification of oxygen; its molecule consists of three oxygen atoms and can exist in all three aggregate states. [48]. Medical ozone is an ozone-oxygen mixture (OOM) obtained from medical oxygen by its decomposition in an electric discharge and consisting of 5% O₃ and 95% O₂. Ozone-oxygen mixtures are produced using special devices - medical ozonizers. In order to minimize the toxic effect of ozone on the body and increase its therapeutic effectiveness when using OOM, it is necessary to know the exact concentration of ozone, the total dose and the time of exposure [63]. Despite the fact that ozone has been actively used for medical purposes for several decades, the mechanisms of its action were established not so long ago and their study continues.

The use of ozone in medicine is based on two fundamental approaches determined by its properties: 1) direct action of ozone, detected during external application in the form of disinfection activity (bactericidal, fungicidal, viricidal properties used to clean wounds, enhance the body's antimicrobial defense and activate local immunity); 2) systemic effect due to low concentrations of ROS induced by ozone (regulation of vasodilation and vasoconstriction, activation of energy metabolism, modulation of oxidation-reduction homeostasis, immunomodulation). Based on the mechanisms of ozone action, methods of using OOM have been developed: 1) external, providing a direct effect of ozone; 2) parenteral, leading to a systemic effect of ozone. External methods of OOM administration include ozone irrigation in a plastic chamber, balneotherapy, various options for using ozonized distilled water and olive oil, intra-articular and para-articular ozone injections, regional lymphotropic administration of OOM. Parenteral methods of administration include major autohemotherapy with OOM (MAHT), minor autohemotherapy with OOM (MAHT), intravenous and lymphotropic drip administration of ozone-saturated saline, intravenous and intra-arterial administration, intramuscular and subcutaneous injections, rectal insufflation of OOM[63].

When high concentrations of gaseous ozone and ozonized solutions are used externally, its powerful oxidizing potential against the bioorganic substrate of microorganisms is manifested. It is believed that the immediate cause of bacterial death under the influence of ozone is local damage to the plasma membrane, leading to the loss of viability of the bacterial cell and (or) its ability to reproduce; in yeast, the main reason is the disruption of intracellular homeostasis. It is important that ozone molecules interact not only with the components of the surface membrane, but, by changing its permeability, lead to the destruction of intracellular organelles. It is also impossible to exclude the mechanism consisting in the action of free oxygen radicals formed during the decomposition of ozone in an aqueous environment, i.e. the one that living organisms use to eliminate foreign antigens. The presence of a highly reactive hydroxyl radical is destructive for most microorganisms [20, 39]. Thus, in vitro experiments have shown that gaseous ozone kills virtually all types of gram-positive and gram-negative bacteria, viruses, fungi and protozoa [9]. According to a number of authors, ozone in concentrations from 1 to 5 mg/l leads to the death of 99.9% of *E. coli*, *Streptococcus faecalis*, *Mycobacterium tuberculosis*, *Cryptosporidium parvum*, *Varavium* and others within 4-20 minutes [54]. Ozone therapy for anaerobic infections is considered pathogenetically justified, a significant number of works are devoted to the use of ozone for the purpose of sanitizing the abdominal cavity in the complex treatment of peritonitis. Thus, O.E. Kolesova [41] notes not only a pronounced clinical, but also a noticeable biochemical effect of abdominal cavity sanitation and intravenous administration of ozonated saline (correction of LPO, AOSZ, increased activity of glucose-6-diphosphoglycerate (G-6-DPG). Significant effects on the phagocytic activity of neutrophils, activation of humoral immunity and a pronounced detoxifying effect of ozone therapy in this group of patients were revealed by B.P. Kudryavtsev [30], S.V. Semenov et al. [50], V.S. Zui et al. [23]. All authors emphasize, along with the clinical, and economic aspects of the use of ozone in purulent surgery - a decrease in bed-day, consumption of expensive antibacterial drugs, antiseptics. According to the unanimous opinion of the authors, the high efficiency of systemic ozone therapy methods, even in the case of a decompensated process, is explained by the normalization of the acid-base balance and lipid peroxidation, elimination of hypoxemia, improvement of tissue oxygenation, and reduction of hyperglycemia that occurs during

treatment. Along with the antibacterial effect, the viricidal effect of ozone has been widely used, which is realized through the oxidation of the surface receptors of the virion, as well as the disruption of the synthesis of viral proteins due to a change in the activity of the reverse transcriptase enzyme [4, 12]. It has also been established that encapsulated viruses are more sensitive to the action of ozone than non-encapsulated ones, which is explained by the large amount of lipids in their capsule (for example, in the herpes virus there are up to 22%), which easily interact with ozone [9]. This circumstance underlies the pronounced therapeutic effects of ozone therapy in recurrent herpes. The most important discovery was the detection of the antiviral effect of ozone on a lymphocyte culture infected with HIV-1 [6]. Researchers explain the mechanism of HIV virus inactivation by the following points: 1) partial destruction of the viral membrane and the loss of its properties; 2) inactivation of the reverse transcriptase enzyme, as a result of which the process of transcription and translation of proteins is inhibited and, accordingly, the formation of new viral cells; 3) disruption of the ability of viruses to bind to receptors of target cells.

Ozone therapy provides increased oxygen delivery to tissues with insufficient blood supply, which has been confirmed by analysis of the gas composition of the blood: the partial pressure of oxygen in venous blood after a course of ozone therapy decreases from 40 to 20 mm Hg [13]. This means that more oxygen is released in tissues suffering from insufficient blood supply - an effect that cannot be achieved with medication. In the mechanisms of antihypoxic action, a certain role is played by vasodilation, which concerns primarily capillaries, arterioles and postcapillary venules. The vasodilating effect of ozone is associated with the release by endothelial cells of the so-called "endothelial vascular relaxation factors", which include nitric oxide. S.P. Peretyagin [42] confirm the positive effect of parenteral ozone on blood circulation and, especially, microcirculation, leading to an increase in the release of oxygen to the tissues. According to their data, after the cessation of treatment, the increased time point of oxyhemoglobin reduction decreases very slowly, over several weeks and even months. Thus, the increased oxygen content in the blood can have a therapeutic effect even when ozone treatment has already been completed.

Improvement of blood rheological properties under the influence of ozone is largely associated with changes in the hemostasis system. It is believed that at the stage of primary (vascular-platelet) hemostasis, a decrease in the aggregation capacity of platelets may be associated with the effect of ozone on the metabolism of arachidonic acid contained in their cell membrane, which, on the one hand, is a source of formation of a powerful activator of platelet aggregation - thromboxane, and on the other - an important inhibitor of thromboxane - prostacyclin in the vascular wall [14]. Ozone is able to activate the platelet enzyme phospholipase A₂, which, by breaking down phospholipids of cell membranes, leads to the release of fatty acids, mainly arachidonic. This acid is a substrate for a number of enzymes, one of which is cyclooxygenase, which converts arachidonic acid into endoperoxide. The further transformation of endoperoxide depends on its localization: in an intact vascular wall it is converted into prostacyclin and prevents the spread of platelet aggregates, and at the site of damage - into thromboxane, which ensures the immediate release of a number of highly active agents that initiate the blood clotting process.

In therapeutic concentrations, ozone is capable of selectively reacting at the site of the double bond in arachidonic acid, triggering its metabolism along the path of prostacyclin

formation, thereby preventing the formation of platelet aggregates [21]. L. V. Shatalina [60] puts forward a hypothesis about free-radical regulation of platelet aggregation activity, and also cites data that diene conjugates can directly activate platelets, leading to their increased aggregation. Thus, ozone administered parenterally, by reducing the level of DC, can contribute to the normalization of the aggregation activity of blood platelets.

A number of studies [52, 53] have established that after a course of ozone therapy, the indices of the first phase of plasma hemostasis - activated recalcification time (ART) and activated partial platelet time (APTT) - increase reliably (within normal values), which indicates a moderate decrease in prothrombinase formation. The above-mentioned shifts, occurring under the influence of ozone therapy, may indicate a decrease in the functional activity of XII, XI, IX and VIII plasma blood coagulation factors. Normalization of the elevated level of fibrinogen, which plays an important role in the aggregation of erythrocytes and platelets, is also noted [24]. E.O. Obukhova et al. [37] describe an increase in fibrinolytic activity, normalization of soluble fibrin-monomer complexes, a decrease in intravascular blood coagulation, and a decrease in total peripheral vascular resistance when using ozone. Some authors presumably associate the vasodilating effect of ozone therapy with the activation of NO synthase and the action of nitric oxide [45]. Thus, by reducing the concentration of fibrinogen, ozone reduces the aggregation of formed elements of the blood and improves its rheological properties, which is essential for the normalization of microhemocirculation. Ozone therapy also affects lipid metabolism: it has been established that ozone oxidizes lipoic acid, which reacts with the activated form of acetaldehyde, resulting [28, 45] in a decrease in the level of lipids in the blood plasma (especially cholesterol and atherogenic fractions of lipoproteins), as well as carbohydrates and a number of under-oxidized products. In many pathological conditions, and especially in the presence of inflammatory processes, the analgesic effect of ozone is clearly expressed, caused, in all likelihood, by the gradual supply of oxygen to the area of inflammation and the oxidation of mediators formed at the site of tissue damage and involved in the transmission of the nociceptive signal to the central nervous system. In the relief of chronic pain syndromes, a major role is also given to the restoration of the balance between the processes of lipid peroxidation and the antioxidant defense system.

Metabolic effects of ozone therapy also occur in the kidneys - it has been established that in nephrocytes ozone intensifies the processes of utilization of glucose, glucose-6-phosphate, lactate, pyruvate with high activity of gluconeogenesis, accumulation of ATP, increase in stability of cell membranes have also been noted [35]. This aspect is of great clinical significance.

The authors emphasize not only the effectiveness of the sanitizing effect of intra-abdominal irrigation with ozonized solutions in inflammatory pathology, but also the advisability of the prophylactic use of ozone. Due to the combined use of local and systemic exposure to ozone, the risk of developing postoperative purulent-inflammatory complications during laparoscopic operations for common forms of genital endometriosis [40] and uterine fibroids [59] is significantly reduced.

Intravaginal and intrauterine methods of introducing ozonized solutions have been described. Thus, intrauterine introduction of ozonized antiseptic solutions, according to L.I. Tsygankova et al. [59], led to a more rapid relief of postpartum endometritis than in the control, normalization of laboratory parameters (ESR, leukocytes, NBT test, levels of lipid peroxidation

products and AOS3, G-6-PDH) in combination with significantly lower consumption of medications, especially antibiotics. The use of ozonized physiological solution in the treatment of patients with inflammatory diseases of the internal genital organs in women is the subject of the work of N.M. Shakhova [61].

Conclusion. Thus, by now many mechanisms of the therapeutic effect of medical ozone have been revealed, its bactericidal, viricidal, fungicidal action, antihypoxic, vasodilating, immunomodulatory, sedative, detoxifying, analgesic effects, the ability to normalize antiradical protection and lipid peroxidation, the structure and functions of cell membranes, etc. have been established. Modern ozone synthesizers and auxiliary means have become widespread, allowing for the implementation of various ozone therapy methods.

References/Литература/Adabiyotlar:

1. Abramovich DR Hofbaner cells - they occupy the cockpit of the placenta / DR Abramovich // European association of Gynaecologists and obstetricians 6-th Meeting, 2011. - P.23.
2. Allaire AD Placentaapoptosis in preeclampsia / AD Allaire, KA Ballcnger, SR Wells, MJ McMahon, BA Lessey // Obstet. Gynecol. - 2014. - V. 96. - P. 271-276.
3. Aplin JD Expression of integrin $\alpha 6 \beta 4$ in human trophoblast and its loss from extravillous cells / JD Aplin // Placenta. -2013. - V. 14. - P. 203-215.
4. Balkanyi A. Interaction between medical ozone and oxygenous radicals, there practical meaning //Proceeding of the IX World Congress.Vol.3. - New- York, 1989. - P. 22-27.
5. Bar J. Effect on fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia and intrauterine growth restriction: Doppler flow study / J. Bar, M. Hod, J. Pardo // Ultrasound Obstet. Gynecol. - 2012. -V.9, №4.- P. 262-265.
6. Carpendale M.T, Griffis J. Is there a role for medical ozone in the treatment of HIV and accosiated infections? //Proceeding of Ozone World Congress. - San Francisco, 1993.-P. 132-145.
7. Cervar M. Endothelin-1 stimulates the proliferation and invasion of first trimester trophoblastic cells in vitro - a possible role in the etiology of pre- eclampsia? / M. Cervar, P. Puerstner, F. Kainer, G. Desoye // J. Invest. Med. - 2012. - V. 44.- P. 447-453.
8. Greenland H.Medical treatment of miscarriage in a district general hospital is safe and effective up to 12 weeks & apos; gestation / H.Greenland, I.Ogunbiyi, G.Bugg// Curr. Med. Res. Opin. - 2013.- Vol.19. - №8. - P. 699 - 701.
9. Konrad H. Ozone therapy for herpes simplex and herpes zoster // Proceeding of the XII World Congress. - Lille, France, 1995. - Vol. 3, - P. 187 - 194.
10. Konrad H. Ozone therapy for viral diseases // Proceeding of the X World Congress. - Monaco, 1991. - P. 75 - 83.
11. Laird SM Stimulation of human endometrial epithelial cell interleukin 6 production by interleukin 1 and placental protein 14 / SM Laird, E. Tuckerman, Li TC Bolton // Hum. Reprod. - 2012 Jul. - Vol.9. - №7. - P. 1339 - 1343.
12. Lippman M. Health effects of ozone, a critical review. //J. Am. Air Pollut. Control Control Assoc. - 1989. - N 39. - P. 672-695.
13. Rokitansky O., Rokitansky A. Electron microscopic studies on capillary endotelluv cells and the peritoneum after application of ozone-oxygen in animals. //Proceeding of the 8th Ozone World Congress. - Zurich. - Switzerland - 1987. - P. 4..
14. Азизова О.А., Власова И.И. Влияние липопртеидов, модифицированных перекисным окислением липидов, на агрегацию тромбоцитов// Бюлл. эксперимент, биологии и медицины . 1993. Т.CXVI. С.485-487.
15. Арустамян Р.Р. Оптимизация ведения послеоперационного периода у женщин после консервативной миомэктомии : Автореф. дис. ... канд. мед. наук. М., 1999.- 20 с.

16. Архипкин Л. В. Оценка состояния фетоплацентарного комплекса при невынашивании беременности / Л.В. Архипкин, А. Ю. Щербаков // Невынашивание беременности: сб. науч. трудов. - М., 2011. - С. 9-12.
17. Балан П. В. Сравнительный анализ устойчивости к острой гипобарической гипоксии новорожденных и взрослых экспериментальных животных / П. В. Балан, А. С. Маклакова, Я. В. Крушинская // Акушерство и гинекология. - 2012. - №2 3. - С. 20-23.
18. Бережанская С. Б. Влияние перинатальной патологии на смертность и заболеваемость детей раннего возраста / С. Б. Бережанская, Н. Б. Андреева // Сб. науч. тр. - М., 2012. - С. 87-92.
19. Витковский Ю.А. Факторы гуморального и клеточного иммунитета при различных физиологических и патологических состояниях / Ю.А. Витковский, Т.Е. Белокриницкая, Б.И. Кузник. - Челябинск, 1995. - С. 28.
20. Гречко Б.Н. Использование озона и озонированных растворов в лечении гнойных ран // Тез. докл. III Всеросс. науч.-прак. конф. «Озон в биологии и медицине» - Н.Новгород, 1998. С.74-75.
21. Грицюк А.И., Амосова Е.Н., Грицюк И.А. Практическая гемостазиология. - Киев: Здоров'я, 1994. - 256 с.
22. Грищенко О.В. Изменение показателей гормонального статуса в беременных женщин с угрозой выкидыша при использовании системной энзимотерапии / А.В. Грищенко, Е.Г. Клименко // Перинатология и педиатрия. - 2012. - № 2. - С.71-73.
23. Зуй В.С., Соколовский С.А. Применение озона при послеоперационных осложнениях //Материалы III Всеросс. науч.-прак. конф. «Озон и методы эфферентной терапии в медицине, -Н.Новгород, 1998, - С.64.
24. Каганов Д.В., Грацианский Н.А. Впервые возникшая стенокардия: роль фибриногена в прогнозировании клинической ремиссии в течение 1-1,5 лет наблюдения//Кардиология. - 1993. - №3. - С. 16-18.
25. Каминский В.В. Сохранение репродуктивного здоровья женщины - основа формирования здоровой нации / В.В. Каминский, Л.Б. Маркин // Здоровье России. - 2008. - №9. С 58-59.
26. Качалина Т.С. Опыт использования озонотерапии в комплексном лечении невынашивания беременности / Т.С. Качалина, Г.О.Гречканев // Акуш. и гин. - 2010. - №3. - С.25 - 29.
27. Ковалева Т.А., Чуйкова К.И., Евтушенко И.Д. и соавт.,2012; Сехин С.В., 2012; Кан Н.Е., Санникова М.В., Амирасланов Э. Ю. и соавт., 2013; Каримова У.А., Олимова Л.И., 2014; Макаров О.В., Бахарева И.В., 2004; Мустафьева А.Г., Кузьмин В.Н., 2015; Балан В.Е., 2017
28. Конторщикова К.Н., Густов А.В., Жулина Н.И., Шевелев Ю.А. Дифференцированное применение озонотерапии у больных с цереброваскулярной патологией. //Тез. Докл. VII Всеросс. съезда неврологов. - 1995.-С.251.
29. Корректирующее действие озона на метаболизм и структуру печени и почек при искусственном кровообращении /Зеленов Д.М., Бояринов Г.А., Перетягин С.П., Монахов А.Н. //Тез. докл. I науч.-прак. конф. «Озон в биологии и медицине» - Н.Новгород, 1992. - С. 22.
30. Кудрявцев Б.П., Сنيгоренко А.С. Лечение синдрома «Кишечном недостаточности» у больных перитонитом методами озонотерапии // Тез докл. III Всеросс. науч.-прак. конф. «Озон в биологии и медицине» - Н.Новгород, 1998. С.70-71
31. Кузьмин В.Н. Акушерская1 тактика у беременных с вирусными инфекциями: Дис.... докт. мед. наук. — М. - 2001.
32. Кулаков В.И., Орджоникидзе Н.В., Тютюнник В:Л. Плацентарная недостаточность и инфекция. — М., 2004. - 294с.

33. Кьюмерле х.п. Клиническая фармакология при беременности / х.п. Кьюмерле. - М., 2011. - Т. 1. - С. 21-22.
34. Л. В. Саркисова -Диагностическая значимость генетических предикторов в прогнозировании преждевременных родов. Бухарский государственный медицинский институт, Бухара, Узбекистан
35. Масленников О.В., Конторщикова К.Н. Озонотерапия: Внутренние болезни: Пособие. - Н.Новгород, 1999. - 56 с
36. Михалевич С.И., Гришкевич А.Н., Марковская Т.В., and Гракович Л.Г.. "Привычное невынашивание беременности: социальная проблема, медицинские решения" Медицинские новости, по. 2, 2012, pp. 12-18.
37. Обухова Е.О., Леванов В.М., Рыхтик П.Б. Возможности озонотерапии в комплексном лечении гипертонической болезни // Тез. докл. II Всеросс. науч.-прак. конф. «Озон в биологии и медицине» - Н.Новгород, 1995.- С. 70–71.
38. Озонотерапия в комплексном лечении больных с острыми воспалительными заболеваниями органов репродуктивной системы /Побединский Н.М., Зуев В.М., Ищенко А.И. и др. // Материалы III Всеросс. науч.-прак. конф. «Озон и методы эфферентной терапии в медицине», - Н.Новгород, 1998,-С.51.
39. Озонотерапия в неотложной хирургии /Васильев И.Т.. Мумладзе Р.Б.. Лебединский И.Н. и др. // Материалы III Всеросс. науч.-прак. конф. «Озон и методы эфферентной терапии в медицине», - Н.Новгород, 1998. - С.60-61.
40. Озонотерапия в хирургии распространенных форм генитального эндометриоза /Ищенко А.И., Бабурина И.П., Ботвин М.А. и др. // Тез. докл. II Всеросс. науч.-прак. конф. «Озон в биологии и медицине» - Н.Новгород, 1995.-С. 63.
41. Озонотерапия разлитого перитонита /Колесова О.Е., Алексеева Л.М., Васильев И.Т. и др. // Тез. докл. II Всеросс. науч.-прак. конф. «Озон в биологии и медицине» - Н.Новгород, 1995.- С. 32 - 33.
42. Перетягин С.П. Влияние озона на углеводный и энергетический обмен в миокарде при гипоксии. //Гипоксия и окислительные процессы: Сборник научных трудов. - Н.Новгород, 1992. - С. 92-98.
43. Плужникова Т.А. Применение препарата Дюфастон у женщин с невынашиванием в анамнезе для подготовки к беременности и лечения угрозы прерывания беременности / Т.А. Плужникова // Журнал акушерства и женских болезней. - 2012. - №2. - С. 54-56.
44. Подтетенев К.С., Оразмурадов 30 А.А., Шишкин Е.А. и соавт., 2011; Лазарева Г.А., Ведощенко Т.В., 2013; Сулеимонова Э.С., Джардемалиева Н.Ж., Кабыл Б.К., 2015
45. Потехина Ю.П. Клинико-экспериментальное обоснование применения озонотерапии у больных компрессионно—ишемическими невропатиями. Дисс. ... канд. мед. наук. Н.Новгород, 1997.
46. Радзинский В.Е., Оразмурадов А.А., Савенкова И.В., Дамирова К.Ф., Хаддад Х. Преждевременные роды — нерешенная проблема XXI века. Кубанский научный медицинский вестник. 2020;27(4):27-37.
47. Разумовский С.Д., Зайков Г.Е. Озон и его реакции с органическими соединениями.- М., Наука, 1974.- 322 с.
48. Рябов С.В., Бояринов Г.А. Исторические аспекты развития озонотерапии. //Тезисы докл. IV Всероссийской научно-практической конференции "Озон и методы эфферентной терапии в медицине". - Н.Новгород, 2000. - С. 1-2.
49. Савельева Г.М. Гемореологии в акушерстве / Г.М. Савельева, Д. Дживилегова, Р.И. Шалина, Н.Н. Фирсов. - М., 2011. - 224 с.
50. Семенов С.В., Снигоренко А.С., Кудрявцев Б.П. Озонотерапия общего перитонита //Материалы IV Всеросс. науч.-прак. конф. «Озон и методы эфферентной терапии в медицине», -Н.Новгород, 2000, - С.72.

51. Сидельникова В.М. Применение препарата Магне-В6 в клинике невынашивания беременности / В.Н. Сидельникова // Акушерство и гинекологии - 2011. - № 6. - С. 47-48.
52. Смирнов А.А. Динамика клинико-физиологических показателей больных дисциркуляторной энцефалопатией в процессе внутривенной озонотерапии: Автореф. дис...канд.мед.наук-Нижний Новгород, 1996. - 20 с.
53. Смирнов А.А., Густов А.В., Конторщикова К.Н. Опыт применения озono-кислородной смеси в комплексном лечении больных дисциркуляторной эн-цефалопатией // Тез. докл. II Всеросс. науч.-прак. конф. «Озон в биологии и медицине» - Н.Новгород, 1995.- С. 78.
54. Сравнительная оценка эффективности озонотерапии при стрептококковых инфекциях в зависимости от способа применения /Алферина Е.Н., Амплеева Н.П., Мамыкина В.М. и др. // Материалы IV Всеросс. науч.-прак. конф. «Озон и методы эфферентной терапии в медицине», -Н.Новгород, 2000. - С. 22.
55. Ткаченко Людмила Владимировна, Костенко Т.И., Углова Н.Д., and Шкляр А.Л. "Невынашивание беременности" Вестник Волгоградского государственного медицинского университета, по. 1 (53), 2015, pp. 3-9.
56. Торопцев И. В. Морфологические особенности и некоторые представления о механизме биологического действия магнитных полей / И. В. Торопцев, С. В. Таранов // Архив патологии. - 2010 - № 2, Т. XIV. - С. 9-11.
57. Тютюнник В.Л. Хроническая плацентарная недостаточность при бактериальной и вирусной инфекции (патогенез, диагностика, профилактика, лечение): Дис. ... докт. мед. наук. — М. — 2002.
58. Федорова М.В. Плацента и ее роль при беременности / М.В. Федорова, Е.П. Калашникова. - М.: Медицина. 2011. - 256 с.
59. Цыганкова Л.И., Безнощенко Г.Б., Катаев А.Ф. Озонотерапия послеродового эндомиометрита // Тез. докл. II Всеросс. науч.-прак. конф. «Озон в биологии и медицине» - Н.Новгород, 1995.- С. 62 - 63.
60. Шаталина Л.В. Перекисное окисление липидов как механизм регуляции агрегационной активности тромбоцитов //Кардиология. - 1993 - №10.-С. 25-28.
61. Шахова Н.М. Применение медицинского озона в комплексном лечении острого течения воспалительных заболеваний внутренних половых органов женщин: Автореф. дисс. канд. мед. наук. - Н.Новгород. - 1996 г. - 25 с.
62. Шехтман М.М. Экстрагенитальная патология. / Шехтман М. М. // 2010. - 810 с.
63. Щербатюк, Т. Г. (2010). Современное состояние озонотерапии в медицине. Перспективы применения в онкологии. Современные технологии в медицине, (1), 99-106.
64. Яковлева Э.Б. Диагностика и лечение фетоплацентарной недостаточности (ФПН) при невынашивании беременности / Е.Б. Яковлева, Б.П. Найкен // Невынашивание беременности: сборная. науч. трудов. - М., 2010. - С. 437-439.
65. Кастуева Н.Д., Цаллагова Л.В., Мерденова Л.А., & Майсурадзе Л.В. (2018). РОЛЬ НОВЫХ МЕДИЦИНСКИХ ТЕХНОЛОГИЙ В АКУШЕРСТВЕ И ГИНЕКОЛОГИИ. Современные вопросы биомедицины, 2 (3 (4)), 132-145.

Received: 1 April 2025
Accepted: 15 April 2025
Published: 10 May 2025

Article / Original Paper

DIAGNOSTIC AND PROGNOSTIC VALUE OF β_2 -MICROGLOBULIN IN CHRONIC KIDNEY DISEASE

Tursunova Laylo Dilshatovna
PhD, Associate Professor

Jabbarov Ozimbay Otaxanovich
DSc, professor, scientific advisor

Tashkent Medical Academy, Tashken

Abstract. In this study, the concentration of β_2 -microglobulin in blood serum was studied in patients with stage I–III chronic kidney disease (CKD). 68 patients and 20 practically healthy individuals, comparable in gender and age, were examined. The level of β_2 -microglobulin was determined by the enzyme immunoassay. The results demonstrated a significant increase in the concentration of β_2 -microglobulin already in the early stages of CKD, followed by an increase as the glomerular filtration rate decreases. An increase in β_2 -microglobulin may reflect both tubular dysfunction and increasing uremic toxicosis. These data emphasize the prognostic significance of β_2 -microglobulin as one of the early markers of CKD progression.

Key words: β_2 -microglobulin, chronic kidney disease, early markers, uremic toxins, CKD progression.

ДИАГНОСТИЧЕСКОЕ И ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ β_2 - МИКРОГЛОБУЛИНА ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК

Турсунова Лайло Дилшатовна
PhD, доцент

Жаббаров Озимбай Отаханович
д.м.н., профессор., научный консультант

Ташкентская медицинская академия, Ташкент

Аннотация. В настоящем исследовании изучена концентрация β_2 -микроглобулина в сыворотке крови у пациентов с хронической болезнью почек (ХБП) I–III стадии. Обследовано 68 больных и 20 практически здоровых лиц, сопоставимых по полу и возрасту. Уровень β_2 -микроглобулина определялся иммуноферментным методом. Полученные результаты продемонстрировали достоверное увеличение концентрации β_2 -микроглобулина уже на ранних стадиях ХБП с последующим нарастанием по мере снижения скорости клубочковой фильтрации. Повышение β_2 -микроглобулина может отражать как канальцевую дисфункцию, так и нарастающий уремический токсикоз. Эти данные подчеркивают прогностическую значимость β_2 -микроглобулина как одного из ранних маркёров прогрессирования ХБП.

Ключевые слова: β_2 -микроглобулин, хроническая болезнь почек, ранние маркёры, уремические токсины, прогрессирование ХБП.

DOI: <https://doi.org/10.47390/3030-3133V3I2Y2025N02>

Хроническая болезнь почек (ХБП) представляет собой прогрессирующее патологическое состояние, сопровождающееся стойким снижением функции почек и морфологическими изменениями нефронов [8,17]. В ранние стадии заболевания, когда клинические проявления минимальны, особое значение приобретает выявление

чувствительных и специфичных биомаркёров, позволяющих своевременно диагностировать нарушение почечной функции и спрогнозировать её дальнейшее прогрессирование [20,26].

Одним из таких маркёров является β_2 -микроглобулин — низкомолекулярный белок, входящий в состав молекул главного комплекса гистосовместимости класса I [4]. В нормальных условиях β_2 -микроглобулин свободно фильтруется в клубочках и почти полностью реабсорбируется и катаболизируется в проксимальных канальцах [5]. При повреждении канальцевого аппарата или снижении скорости клубочковой фильтрации его уровень в крови возрастает. Кроме того, накопление β_2 -микроглобулина отражает развитие уремического токсикоза и системного воспаления, что усиливает его прогностическую ценность в оценке тяжести и прогрессии ХБП [6,7,27].

В условиях прогрессирования хронической болезни почек наблюдаются не только структурные и функциональные нарушения клубочкового аппарата, но и прогрессирующее поражение канальцев и интерстиция, которое нередко предшествует снижению скорости клубочковой фильтрации [1-3]. В связи с этим возрастает интерес к маркёрам, отражающим степень повреждения канальцевого эпителия. Среди них β_2 -микроглобулин занимает особое место благодаря своей высокой чувствительности к канальцевой дисфункции, особенно на ранних стадиях ХБП, когда традиционные биохимические показатели могут оставаться в пределах нормы [9,13].

Кроме диагностической ценности, β_2 -микроглобулин рассматривается как потенциальный прогностический биомаркер, поскольку его стойкое повышение коррелирует с ухудшением почечной функции, повышенным риском сердечно-сосудистых осложнений и общей смертности [12,23]. Это подчёркивает необходимость включения β_2 -микроглобулина в панель лабораторных маркёров при комплексной оценке состояния пациентов с ХБП, особенно в тех случаях, когда требуется динамическое наблюдение и стратификация риска прогрессирования заболевания [22,25].

Несмотря на наличие данных о β_2 -микроглобулине при терминальной почечной недостаточности, его роль на доклинических и ранних стадиях ХБП остаётся менее изученной. В этой связи представляет интерес изучение уровня β_2 -микроглобулина у пациентов с ХБП I–III стадии для оценки его значимости как раннего маркёра нарушений почечной функции и возможного предиктора дальнейшего ухудшения состояния.

Цель: определить уровень β_2 -микроглобулина у пациентов с ХБП I–III стадии для оценки его значимости как раннего маркёра нарушений почечной функции и возможного предиктора дальнейшего ухудшения состояния.

Материалы и методы

В исследование были включены 68 пациентов с хронической болезнью почек (ХБП) I–III стадии, находившиеся под наблюдением в нефрологическом отделении, и 20 практически здоровых лиц, сопоставимых по полу и возрасту, составивших контрольную группу. Критериями включения служили наличие подтверждённого диагноза ХБП согласно рекомендациям KDIGO (2012) [15], стабильное течение заболевания и отсутствие острых воспалительных состояний на момент обследования. Из исследования исключались пациенты с острыми инфекциями, онкологическими

заболеваниями, декомпенсированным сахарным диабетом и выраженной сердечно-сосудистой патологией.

Стадии ХБП определялись на основании расчёта скорости клубочковой фильтрации (СКФ) с использованием формулы СКД-EPI [15]. Группы распределялись следующим образом:

- ХБП I стадии (СКФ ≥ 90 мл/мин/1,73 м² + признаки поражения почек),
- ХБП II стадии (СКФ 60–89 мл/мин/1,73 м²),
- ХБП III стадии (СКФ 30–59 мл/мин/1,73 м²).

Уровень β_2 -микроглобулина в сыворотке крови определяли методом твердофазного иммуноферментного анализа (ELISA) с использованием стандартных коммерческих наборов (например, Human β_2 -Microglobulin ELISA Kit, Bioassay Technology Laboratory, Китай), согласно инструкции производителя [9]. Забор крови производился натощак, центрифугирование проводилось при 3000 об/мин в течение 10 минут, образцы хранились при –80°C до проведения анализа.

Все пациенты прошли комплексное клиничко-лабораторное обследование, включающее стандартные биохимические и общеклинические показатели. Статистическая обработка данных осуществлялась с использованием программы IBM SPSS Statistics 26.0. Проверка распределения признаков проводилась с использованием критерия Шапиро–Уилка. Для сравнения количественных показателей между группами применялся t-критерий Стьюдента (при нормальном распределении) или критерий Манна–Уитни. Достоверность различий принималась при $p < 0,05$.

Результаты

В ходе исследования были оценены уровни β_2 -микроглобулина у пациентов с различными стадиями хронической болезни почек (ХБП). Были сформированы следующие группы: контрольная группа (здоровые участники), пациенты с ХБП 1 стадии, ХБП 2 стадии и ХБП 3 стадии. В контрольной группе ($n=20$) средний уровень β_2 -микроглобулина составил $1,35 \pm 0,28$ мг/л. Этот показатель был в пределах нормы, что свидетельствует о нормальной функции почек у здоровых испытуемых. У пациентов с ХБП 1 стадии ($n=20$) средний уровень β_2 -микроглобулина составил $1,87 \pm 0,33$ мг/л. Этот показатель был значительно выше, чем в контрольной группе, что подтверждает наличие раннего повреждения почек, несмотря на нормальные значения скорости клубочковой фильтрации (СКФ). При ХБП 2 стадии ($n=25$) уровень β_2 -микроглобулина был еще более повышен и составил $2,41 \pm 0,45$ мг/л. Данный результат указывает на дальнейшее ухудшение почечной функции, поскольку β_2 -микроглобулин является маркером повреждения почек и его уровень увеличивается с прогрессированием заболевания. Пациенты с ХБП 3 стадии ($n=23$) продемонстрировали наибольшее повышение уровня β_2 -микроглобулина — $3,16 \pm 0,52$ мг/л. Это соответствует более выраженному нарушению функции почек и подтверждает тесную связь между повышением уровня β_2 -микроглобулина и прогрессированием хронической болезни почек (табл.1).

Анализ данных показал, что уровень β_2 -микроглобулина имеет обратную корреляцию с показателями СКФ ($p < 0,001$, $r = -0,35$). По мере снижения СКФ (с 95 мл/мин/1,73 м² на 1 стадии до 45 мл/мин/1,73 м² на 3 стадии) уровень β_2 -

микроглобулина увеличивался, что подтверждает его роль как маркера повреждения почек и прогрессирования заболевания (рис.1).

Таблица 1

Уровень β_2 -микроглобулина в сыворотке крови и СКФ у обследованных групп

Группа (n- количество больных)	Средняя СКФ (мл/мин/1,73 м ²)	β_2 -микроглобулин, мг/л (M $\pm$ SD)	p (по сравнению с контролем для β_2 -микроглобулин)
Контрольная группа (n=20)	108,3 $\pm$ 6,2	1,35 $\pm$ 0,28	-
ХБП I стадии (n=20)	95,2 $\pm$ 4,7	1,87 $\pm$ 0,33	< 0,05
ХБП II стадии (n=25)	75,1 $\pm$ 11,5	2,41 $\pm$ 0,45**	< 0,01
ХБП III стадии (n=23)	48,3 $\pm$ 10,9*	3,16 $\pm$ 0,52**^	< 0,001

Примечание: *-p < 0,01 **-p < 0,001 по сравнению с ХБП II стадии, ^-p < 0,01 по сравнению с ХБП I стадии.




Рис. 1. ROC-кривые с 95% доверительным интервалом для β_2 -микроглобулин относительно СКФ.

Обсуждение. Результаты нашего исследования подтверждают, что уровень β_2 -микроглобулина может быть использован в качестве маркера для диагностики и мониторинга хронической болезни почек (ХБП), поскольку его концентрация коррелирует с ухудшением функции почек, а также прогрессированием заболевания. Уровень β_2 -микроглобулина в крови повышается с прогрессированием стадии ХБП, что делает его потенциальным прогностическим инструментом для оценки состояния пациента.

β_2 -микроглобулин (β_2 -МГ) — это малый молекулярный вес белка, который присутствует на поверхности клеток, а также выделяется почками. В нормальных условиях β_2 -микроглобулин фильтруется в почках и почти полностью реабсорбируется. Однако при почечном повреждении этот процесс нарушается, что приводит к повышению его уровня в крови [12]. Повышение уровня β_2 -микроглобулина

наблюдается на всех стадиях ХБП, но наиболее выражено на поздних стадиях, когда почечная фильтрация значительно снижена.

Наши результаты показали, что уровень β 2-микроглобулина значительно увеличивается с прогрессированием ХБП. Это согласуется с работами других авторов, которые установили, что уровень β 2-микроглобулина возрастает при всех стадиях ХБП и особенно значительно повышается на стадии 3 и выше [18,21]. В нашем исследовании уровень β 2-микроглобулина был наибольшим у пациентов с ХБП 3 стадии, что соответствует данным других исследований, подтверждающих его роль как индикатора почечного повреждения и прогрессирования заболевания.

Наша работа совпадает с результатами нескольких крупных исследований, которые исследовали роль β 2-микроглобулина в ХБП. Например, в исследовании, проведенном в 2018 году, было показано, что уровень β 2-микроглобулина статистически значимо повышается на 2 и 3 стадиях ХБП, и он может служить индикатором прогрессирования заболевания [16]. Также, в более раннем исследовании, проведенном в 2015 году, β 2-микроглобулин был предложен как эффективный маркер для мониторинга почечного повреждения у пациентов с диабетической нефропатией [23].

В другом исследовании 2020 года, где изучались различные биомаркеры при ХБП, β 2-микроглобулин показал высокую чувствительность и специфичность при диагностике ХБП, особенно в случаях с нормальной или умеренно сниженной СКФ, когда другие маркеры, такие как креатинин, могут не отражать реальное состояние почечной функции [20].

Наше исследование также показало значительную корреляцию между уровнем β 2-микроглобулина и показателями СКФ, что согласуется с работами других авторов (7). В частности, исследование, проведенное в 2019 году, также показало, что β 2-микроглобулин может быть полезен в сочетании с другими маркерами (например, цистатином С) для улучшения диагностики ХБП, особенно на ранних стадиях заболевания [17].

Корреляция между уровнем β 2-микроглобулина и СКФ подчеркивает важность этого маркера для ранней диагностики почечного повреждения, когда другие маркеры могут не давать четкого представления о нарушении функции почек. Например, креатинин, хотя и является одним из наиболее часто используемых маркеров почечной функции, может быть менее чувствительным на ранних стадиях ХБП, когда его уровни находятся в пределах нормы [26]. Кроме того, β 2-микроглобулин может служить не только диагностическим, но и прогностическим маркером ХБП. Ряд исследований показал, что высокий уровень β 2-микроглобулина может предсказать ухудшение функции почек в будущем. В исследовании, проведенном в 2017 году, пациенты с высокими уровнями β 2-микроглобулина имели более высокие шансы на развитие почечной недостаточности [11]. Эти данные подчеркивают важность β 2-микроглобулина для оценки прогноза заболевания.

Включение β 2-микроглобулина в стандартное обследование пациентов с ХБП может значительно повысить точность диагностики и прогноза. Особенно важно учитывать этот маркер на ранних стадиях ХБП, когда другие клинические показатели,

такие как СКФ и уровень креатинина, могут не отражать всех изменений в почечной функции.

Заключение

Результаты нашего исследования подтверждают, что уровень β 2-микроглобулина является важным маркером, который может быть использован для диагностики и мониторинга ХБП. Мы установили значительное повышение уровня β 2-микроглобулина с прогрессированием заболевания, что согласуется с результатами других исследований. Включение β 2-микроглобулина в клиническую практику может помочь улучшить диагностику, мониторинг и прогнозирование хронической болезни почек.

Литература/Referenses/Adabiyotlar:

1. Авганбекова Г.М., Турсунова Л.Д., Жаббаров О.О. ЗАВИСИМОСТЬ АНГИОГРАФИЧЕСКИХ ХАРАКТЕРИСТИК ПОРАЖЕНИЙ КОРОНАРНЫХ АРТЕРИЙ ОТ ФАКТОРОВ РИСКА СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У БОЛЬНЫХ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ //SCHOLAR. – 2025. – Т. 3. – №. 1. – С. 108-115.
2. Жаббаров О. О., Турсунова Л. Д., Хужаниязова Н. К. ВНУТРИПОЧЕЧНАЯ ГЕМОДИНАМИКА ПРИ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ //Академические исследования в современной науке. – 2024. – Т. 3. – №. 44. – С. 114-115.
3. Мирзаева, Ш. Х., et al. "Сурункали буйрак касаллиги бўлган беморларда кардиоренал синдромни даволаш." (2022).
4. Bataille R., Klein B. The role of beta 2-microglobulin in multiple myeloma. *Blood*. 1986;68(3):583–586.
5. Bernard A.M. Clinical significance of urinary proteins in nephrology. *Clin Nephrol*. 1989;32(1):42–46.
6. Cohen G., Haag-Weber M., Hörl W.H. Immune dysfunction in uremia. *Kidney Int Suppl*. 1997;62:S79–S82.
7. Cummings J, et al. (2018). "Use of β 2-microglobulin in the evaluation of chronic kidney disease." *Nephrology Review*, 16(2), 22-28.
8. Eckardt K.U., Coresh J., Devuyst O., et al. Evolving importance of kidney disease: from subspecialty to global health burden. *Lancet*. 2013;382(9887):158–169.
9. Erlandsen E.J., Randers E., Kristensen J.H. Reference intervals for serum beta2-microglobulin and cystatin C in adults. *Clin Chem Lab Med*. 1998;36(11):905–909
10. Filler G., Priem F., Lepage N., et al. β 2-Microglobulin in renal disease. *Clin Biochem*. 2001;34(4):237–247.
11. Garcia-Garcia, G., et al. (2017). "Prognostic value of β 2-microglobulin for end-stage renal disease." *Nephrology*, 22(8), 675-683.
12. Han WK, et al. (2002). "Urinary biomarkers for early detection of acute kidney injury." *Kidney International*, 62(4), 1205-1212.
13. Hsu C.Y., Chertow G.M. β 2-Microglobulin predicts mortality in chronic kidney disease. *Clin Nephrol*. 2006;66(4):235–241.
14. Jabbarov O. O. Disorders Function of the Heart and Kidney in Diabetes Mellitus. – 2023.
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl*. 2013;3(1):1–150.
16. Kao, C.-Y., et al. (2019). "Correlation of β 2-microglobulin and cystatin C in kidney function assessment." *Kidney International*, 56(5), 2085-2092.
17. Lee S, et al. (2019). " β 2-microglobulin as a prognostic marker in chronic kidney disease." *Clinical Journal of the American Society of Nephrology*, 14(9), 1301-1308.

18. Levey AS, et al. (2007). "Chronic kidney disease: basic principles and clinical practice." *The Lancet*, 370(9582), 939-953.
19. Levin A., Stevens P.E. Summary of KDIGO 2012 CKD Guideline: A clinical practice approach. *Kidney Int.* 2014;85(5):879-883.
20. Liu Y, et al. (2020). "β2-microglobulin in chronic kidney disease: Its role in diagnosis and prognosis." *Clinical Nephrology*, 93(3), 137-144.
21. Maduell F, et al. (2018). "β2-microglobulin as a diagnostic marker for chronic kidney disease." *Nephrology Dialysis Transplantation*, 33(4), 701-707.
22. Matsushita K., van der Velde M., Astor B.C., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality. *Lancet.* 2010;375(9731):2073-2081.
23. O'Neill WC, et al. (2015). "β2-microglobulin: A key marker for kidney disease in diabetes." *Diabetes Care*, 38(6), 1105-1112.
24. Schardijn G.H., Statius van Eps L.W. Beta2-microglobulin: its significance in the evaluation of renal function. *Kidney Int.* 1987;32(5):635-641.
25. Shinkai S., Chaves P.H., Fujiwara Y., et al. β2-Microglobulin and mortality among older adults in the community. *Clin Exp Nephrol.* 2006;10(4):282-288.
26. Thomas R, et al. (2018). "Limitations of creatinine in the diagnosis of kidney disease." *Nephrology and Dialysis Transplantation*, 33(4), 707-715.
27. Tursunova L. D., Jabbarov O. O. APPLICATION OF SAKABUTRIL/VALSARTAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH TYPE 2 DIABETES MELLITUS //Art of Medicine. International Medical Scientific Journal. – 2021. – T. 1. – №. 1.
28. Tursunova L., Jabbarov O. O. THE ROLE OF RENAL VASCULAR DOPPLEROGRAPHY IN THE DIAGNOSIS OF CHRONIC KIDNEY DISEASE //Медицинский журнал молодых ученых. – 2024. – №. 12 (12). – С. 52-57.
29. Wong J.Y., Lee S., Choi M.J. Serum and urinary beta-2 microglobulin levels in chronic kidney disease. *Korean J Intern Med.* 2015;30(3):476-484.
30. Erlandsen E.J., Randers E., Kristensen J.H. Reference intervals for serum beta2-microglobulin and cystatin C in adults. *Clin Chem Lab Med.* 1998;36(11):905-909

Received: 1 April 2025
Accepted: 15 April 2025
Published: 10 May 2025

Article / Original Paper

IMPORTANCE OF VAGINAL MICROBIOME IN REPRODUCTION

Bektemirova Begoyim Baxtiyorjon qizi

FMIPH 1st year PhD student

Abstract: Vaginal microbiome's role in reproductive function of women is one of the most important topics nowadays. Thanks to sequencing based technology it is possible to identify variety of microorganisms which was impossible with help of cultural methods. Now both reproductive technology and vaginal microbiome become the most discussed topic in science. This review analysis impact of vaginal microbiome on reproductive outcomes. Usually, non Lactobacillus dominated microbiome is associated with dysbiosis and bacterial vaginosis. These changes in microbiome may result in implantation failure, recurrent pregnancy loss, missed abortion. Thus, analyzing vaginal microbiome and correcting it with antibiotics and probiotics may improve reproductive outcomes.

Key words: pregnancy, ART, implantation failure, recurrent pregnancy loss, missed abortion.

REPRODUKTIV FAOLIYATDA QIN MIKROBIOMINING AHAMIYATI

Bektemirova Begoyim Baxtiyorjon qizi

Farg'ona jamoat salomatligi tibbiyot instituti 1-kurs tayanch doktoranti

E-mail: bektemirovabegoyimbaxtiyorqizi@gmail.com

Annotatsiya. So'nggi yillarda inson mikrobiomiga tobora ko'proq e'tibor berilmoqda. Sekvensiyaga asoslangan texnologiyaning yaratilishi avval muhitlarga ekish orqali aniqlash qiyin bo'lgan ko'p sonli bakteriyalarni aniqlash imkonini berdi. Mikroboim diagnostikasi fanning asosiy yo'nalishi sifatida paydo bo'ldi, shu bilan birga reproduktiv tibbiyot ham rivojlandi. Ayniqsa, implantatsiya yetishmovchiligi sabablarni tadqiq qilish va davolash imkoniyatlari bilan bog'liq tadqiqotlar ko'paydi. Shunday qilib, vaginal mikrobiom bepushtlikka ta'sir qiluvchi omil sifatida muhokama qilinadi va davolash imkoniyatlari uchun istiqbolli yo'l hisoblanadi. Ushbu sharh qin mikrobiomining reproduktiv natijalarga ta'sirini ko'rsatuvchi zamonaviy tadqiqotlar natijalarini tahlil qiladi. Laktobakteriyalar ustun bo'lmagan mikrobiom disbioz bilan hatto bacterial vaginoz bilan bog'liq ekanligi ko'rsatilgan, Ushbu nomutanosiblik implantatsion yetishmovchilik, odatlangan homila tushishi, rivojlanmagan homiladorlikka olib kelishi mumkin. Shu sababli, mikrobiomni tekshirish hamda antibiotiklar va/yoki probiotiklar bilan birgalikda davolash reproduktiv natijalarini yaxshilash usuli bo'lishi mumkin.

Kalit so'zlar: yordamchi reproduktiv texnologiyalar; qin mikrobiomi; implantatsiya yetishmovchiligi; disbioz; homiladorlik, rivojlanmagan homiladorlik.

DOI: <https://doi.org/10.47390/3030-3133V3I3Y2025N03>

Kirish

Yordamchi reproduktiv texnologiyalar bepushtlik muammosiga duch kelgan juftliklar uchun keng tarqalgan va istiqbolli davolash usuli hisoblanadi. Texnologiyaning muvaffaqiyatiga bir qancha texnik sharoitlar bilan birga haqiqiy reproduktiv salohiyat (oosit, spermatozoidalar va embrionning implantatsiyasi va rivojlanishini ta'minlovchi onalik muhitining sifati) ta'sir qiladi. Shunday qilib, uchta noyob fiziologik muhit ishtirok etadi. Biroq, muvaffaqiyat uchun mas'ul bo'lgan hal qiluvchi omillar endometriy, uning mikrobiomi va immunologik aspektlar hisoblanadi. Biz inson mikrobiomi haqida ko'proq ma'lumotga ega bo'lganimiz sayin, u insonning deyarli har bir fiziologik faoliyatiga ta'sir qilishi ma'lum bo'ldi[1].

Bakteriyalar, arxeyalar, zamburug'lar, faglar va viruslar kabi milliardlab mikroblar inson tanasi kolonizatsiya qiladi[2]. Kolonizatsiya qiluvchi patogen bo'lmagan bakteriyalarga oid birinchi tadqiqotlar 1885-yilda nashr etilgan bolalar ichagidagi ichak tayoqchasi *E.coli* haqida edi[3]. Bu tadqiqotdan keyin XX asr davomida boshqa kommensal bakteriyalar, inson tanasining turli qismlarida, masalan, burun va og'iz bo'shliqlari, teri va siydik-jinsiy yo'llarda yashovchi bakteriyalar tadqiq qilingan[3]. Lekin ularning ahamiyati yo'q deb hisoblangan. Umuman olganda, olimlar mikroblarni inson salomatligiga tahdid sifatida qabul qilgan. 1988-yilda Whipps va boshqalar. mikrobiom atamasiga "aniq fizik-kimyoviy xususiyatlarga ega bo'lgan, yetarli darajada aniq belgilangan yashash muhitini egallagan mikroblar jamoasi" deb ta'rif bergan. Keyinchalik bu ta'rif mikroblar faoliyati va dinamikasini hisobga olib yanada boyitildi[4]. Hozirda mikrobiot va mikrobiom atamalarini farqlash muhimdir: mikrobiot m'lum bir muhitdagi mikroorganizmlar jamoasini anglatadi, mikrobiom esa mikroorganizmlar jamoasini ularning atrof-muhit sharoitlarini hisobga olgan holda ma'lum bir muhitdagi roli va ularning o'zaro ta'sirini hisobga olgan holda tavsiflaydi.

Inson mikrobiotining 80%i ovqat hazm qilish yo'lida joylashgan bo'lsa, umumiy mikrobiotning 9%i urogenital trakti kolonizatsiya qiladi [5,6]. Siydik chiqarish yo'llari ilgari steril deb hisoblangan, ammo bugungi kunda biz aniq bakterial jamoalar siydik yo'llarida sog'lom siydik muhiti uchun javobgar ekanligini bilamiz. Bu mikrobiomdagi o'zgarishlar siydik tuta olmaslik, urologik o'smalar, siydik pufagi neyrogen disfunktsiyasi bilan bog'liqdir [7]. Qin mikrobiomida *Lactobacilli* yetakchilik qiladi va bu ko'pincha urogenital a'zolarining normal holati bilan birga keladi. *Lactobacilli* laktat kislota ishlab chiqaradi va bu qin pH ni kislotali saqlashga, boshqa mikroorganizmlarning o'sishini cheklashga sababchi asosiy omildir. Yaqin vaqtlargacha bachadon bo'shlig'i steril deb hisoblangan. Ammo u qin mikrobiotiga nisbatan 100-1000 marta kamroq miqdorda, ammo undan ko'ra xilma-xil mikroorganizmlar mikrobiotini saqlaydi. Bachadon bo'shlig'i mikrobiotida *Lactobacill*ining qin mikrobiomidan ko'ra boshqacharoq turlari dominantlik qiladi[3,8,9]. Bachadon bo'shlig'idagi mikroorganizmlar uni infeksiyadan himoya qiladi va muddatdan oldingi tug'ruq, implantatsiya yetishmovchiligi kabi holatlar bilan bog'liq[10].

Qin mikrobiomi keng qiziqishlarga sabab bo'lmoqda. Chunki uning reproduktiv natijalar, ayollar salomatligidagi o'rnini o'rganish muhimdir[11]. Ushbu sharhning maqsadi qin mikrobiomi va reproduktiv natijalar, implantatsion yetishmovchilik, odatlangan homila tushishi, rivojlanmagan homiladorlik orasidagi bog'liqlik, disbiozni davolashga qaratilgan tadqiqotlarni tahlil qilishdir.

Tadqiqot usullari

Qin mikrobiomini o'rganish muhitlarga ekish yoki sekvensiyaga asoslangan texnologiyalar yordamida amalga oshirilishi mumkin. Avvalgi tadqiqotlarda odam organizmi mikrobiomini o'rganish muhitlarga ekish orqali o'rganilgan. Bunda o'sayotgan koloniyalarning o'sish xususiyatlari, biokimyoviy, morfologik xususiyatlari asosida mikroorganizmlar farqlangan [12]. Ammo bu usul ko'p vaqt talab qiladi hamda hamma mikroorganizmni aniqlash imkonini bermaydi[13]. Shu sababli bu usuldan tadqiqotlarda foydalanish yetarli natijalar bermaydi. Ammo kunlik tibbiyotda kultura olish usuli keng qo'llaniladi. Sababi undan keng ko'lamli foydalanish mumkin. Shunga qaramay, bu usul mikroorganizmlarning o'zaro aloqasini ko'rsatmaydi [14].

Muhitlarda o'smaydigan bakteriyalarni molekulyar usul bilan aniqlash mumkin [15,16]. 16S ribosomali RNK (rRNK) bilan bog'liq genlarning ketma-ketligi mikrobiomni o'rganishda yangicha yondashuv hisoblanadi [17]. Xususan, 16S rRNK prokariotik ribosomaning 30S kichik bo'linmasining tarkibiy qismidir va bu komponentni kodlovchi genlar genomik evolyutsiyaning sekin tezligi tufayli filogeniyalarni qayta tiklash uchun ishlatiladi [17]. Xususan, molekulyar barmoq izlari bo'lib xizmat qiladigan gen ichidagi gipero'zgaruvchan hududlar avlod va tur darajasini aniqlash uchun foydalaniladi [18,19]. Bu ketma-ketlikka asoslangan texnologiya DNKni to'g'ridan-to'g'ri ekstraksiya va klonlash orqali fiziologiyasi haqida qo'shimcha ma'lumot olish uchun mikroorganizmlarni aniqlash imkonini beradi [1]. Metagenomika ma'lum bir muhitdagi barcha mikroblarning butun genomini ifodalaydi, bir hujayrali genomika esa alohida hujayralar genomlariga ishora qiladi. Ushbu tadqiqotlarning muvaffaqiyati birinchi navbatda berilgan namunalardan ajratilgan metagenomik DNK miqdori va sifatiga bog'liqdir. Shuning uchun, berilgan namunadan yaxshi sifatli metagenomik DNKni ajratib olish qiyin vazifa hisoblanadi [20].

Reproduktiv yoshdagi sog'lom ayol qin mikrobiomi xususiyatlari

Vaginal mikrobiom va uning reproduktiv tizimga ta'sirini batafsil ko'rib chiqishdan oldin uning fiziologik holatini tushunish muhimdir. Vaginal mikrobiom ayol organizmini turli zamburug'lar, bacterial va virusli patogenlardan himoya qiladi va pastki reproduktiv tizimda tashqi muhitga qarshi birinchi to'siqni hosil qiladi. Tabiiy yo'l bilan tug'ish holatlarida vaginal mikrobiom yangi tug'ilgan chaqaloqqa kolonizatsiyalanadi, shuning uchun chaqaloqning immunitet tizimiga ta'sir qiladi va himoya qiladi. Yangi tug'ilgan chaqaloqning immunitet hujayralarida kolonizatsiya tabiati va darajasi bo'yicha, turli mikroblar populyatsiyalari turli xil induksiyalarni keltirib chiqaradi. Bundan tashqari, mikroorganizmlarga ta'sir qilish hayotning boshida immunitet tizimini shakllantirish uchun muhim ahamiyatga ega [21]. Vaginal mikrobiom chaqaloqning neyro rivojlanishida ham muhim rol o'ynaydi. Mikrobiot giston deasetilazlarni (HDAC) tormozlashi, mikroglia ta'sir qilishi, neyrotransmitterlarni ishlab chiqarishi, qon-miya to'sig'i orqali o'tishi va qisqa zanjirli yog' kislotalari (SCFA) bilan o'zaro ta'sir qilishi aniqlangan. Bu omillar miya rivojlanishida muhim rol o'ynaydi [22,23]. *Lactobacillus* turlari har qanday yoshdagi qinda oz miqdorda mavjud bo'lib, bu tuxumdon gormonlarining ta'siri bilan amalga oshadi. Laktobakteriyalar turlari 1 gramm qin suyuqligida 10^7 - 10^8 koloniya hosil qiluvchi birlik miqdorida uchraydi. Estrogen ta'sirida qin hujayralari ko'payadi, ularda glikogenni sezilarli darajada ushlab turadi va progesteron bu hujayralarning sitolizini rag'batlantiradi. Shunday qilib, glikogen laktobakteriyalar tomonidan glyukoza va maltozaga parchalanadi. Bu bir nechta metabolik mahsulotlarni, shu jumladan laktatni ishlab chiqaradi va fiziologik kislotali pH ni hosil qiladi [24]. Sut kislotasi ishlab chiqarish normal vaginal mikrobiomaning o'ziga xos belgisidir, chunki natijada vaginal pH ($\sim 4,0$) patogen bakteriyalarning o'sishi uchun noqulay muhit yaratadi [25]. In vivo vaginal laktatning o'rtacha konsentratsiyasi $0,79 \pm 0,22\%$ ni tashkil qiladi, fiziologik pH ni $3,8 \pm 0,2$ [26] keltirib chiqaradi. Shunday qilib, sut kislotasi giston deasetilazlarni bloklaydi, gen transkripsiyasini va DNK reparatsiyasini kuchaytiradi. Epiteliy hujayralarida otofagiyaning keltirib chiqaradi va gomeostazni rag'batlantiradi [27]. Bacterial vaginozda ishtirok etgan bakteriyalarni sut kislotasi yo'q qila oladi [28].

Laktobakteriyalar uzun yoki qisqa Gram-musbat tayoqchalar bo'lishi mumkin, ba'zan sharsimon (kokkoid) bo'lishi ham mumkin. Ular sitokinlarni keltirib chiqaradi va vaginal

epiteliy (masalan, Langerhans hujayralari yoki dendritik hujayralar) immun hujayralari bilan o'zaro bog'lanadi, laktat hosil qiladi. Shuningdek, H₂O₂, biosurfaktanlar va koaggregatsiya molekulalari fakultativ patogen bakteriyalardan himoya qiladi[27].

Vaginal mikrobiom turli etnik guruhlarda va tadqiqotlarda tahlil qilindi va mikrobiotning xilma-xil tarkibi aniqlandi [29,30]. Bu klinik kontekstda muhim ahamiyatga ega ko'rinadi, chunki mikrobial tarkibdagi farqlar tegishli vaginal muhit infeksiyaga javob berishi yoki boshqa nomutanosibliklar bilan o'zaro ta'sir qilishiga turlicha ta'sir qilishi mumkin. Etnik kelib chiqishidan tashqari, mikrobiomga fiziologik hodisalar ham ta'sir qiladi, masalan: hayz davri va homiladorlik, shuningdek tashqi omillar, masalan, jinsiy faollik, gigiyena odatlari va tibbiy muolajalar [31].

Verhelst va boshqalar Gram bo'yash va 16S rRNA ketma-ketligi kombinatsiyasidan foydalangan holda 197 homilador ayolning vaginal mikrobiomasini tahlil qildi va tegishli dominant Lactobacillus turlarida farqlarni aniqladi [32]. Laktobakteriyalarning quyidagi to'rtta asosiy turi aniqlangan: Lactobacillus crispatus (L. crispatus), Lactobacillus iners (L. iners), Lactobacillus jensenii (L. jensenii) va Lactobacillus gasseri (L. gasseri) [16]. Hozirda biz Lactobacillusning 261 turi borligini bilamiz, ularning ba'zilariga 2020 yilda yangi nomlar berildi [33].

Vaginal mikrobiom tarkibiga va dominant Lactobacillus turlariga qarab guruhlariga bo'linishi mumkin. Ravel va boshqalar Community state type (CST) deb ataluvchi I, II, III, IV va V sifatida belgilangan, hamda mos ravishda 105, 25, 135, 108, va 21 ta mikrob taksoni [25,29] saqlovchi beshta guruh ajratishdi. I sinf Lactobacillus crispatus ustunligi bilan ajralib turardi va tahlil qilingan aholining 26,2 foizida topilgan, II daraja (6,3%), III (34,1%) va V (5,3%) esa mos ravishda Lactobacillus gasseri, Lactobacillus iners va Lactobacillus jensenii dominantligi bilan aniqlangan [29]. Ushbu 4 sinflar asosan Osiyo va Yevropa oq tanli ayollaridan ajratib olingan. IV sinf esa asosan qora tanli va ispan ayollarda uchraydi hamda laktobakteriyalar dominantligi yo'qligi bilan ifodalanadi. Bu sinfdan anaeroblar — Gardnerella, Prevotella, Corynebacterium, Atopobium, Megasphaera, Sneathia ko'p uchraydi. Tadqiqotlarda IV sinf va muddatdan oldingi tug'ruqlar o'rtasida o'zaro bog'liqlik aniqlangan[33,34].

Qin mikrobiomi va rivojlanmagan homiladorlik

Vaginal mikrobiomdagi o'zgarishlar va implantatsiya yetishmovchiligi o'rtasidagi bog'liqlik vaginal mikrobiom va rivojlanmagan homiladorlik o'rtasidagi bog'liqlikdan ko'ra kengroq ko'rib chiqilgan. Mavzuga bag'ishlangan kam sonli tadqiqotlar kichik ko'lamda o'tkazilgan. Odatlangan homila tushishi 12 haftalik homiladorlik davridan oldingi ketma-ket 3 marta va undan ko'p homila tushishi bilan ta'riflanadi va 1-2% holda kuzatiladi [35,36]. Amerika Reproktiv Tibbiyot Jamiyatiga ko'ra odatlangan homila tushishi ayollarda ikki yoki undan ortiq homiladorlikning klinik (ultratovush yoki gistopatologiya) dalillari bilan homiladorlik yo'qolganidan keyin tashxis qo'yilishi mumkin [37]. Fan va boshqalar rivojlanmagan homiladorlik bor 31 bemorning 16S rRNA ketma-ketligi yordamida vaginal mikrobiomini tahlil qildi va ularni oddiy homila tushishini boshdan kechirgan 27 ayol bilan solishtirgan [38]. Mualliflar rivojlanmagan homiladorlik guruhidagi bemorlarda tez-tez vaginal infeksiyalarga duchor bo'lishlarini kuzatdilar, masalan bakterial vaginoz, kandidoz yoki mikoplazma infeksiyasi. Bularning barchasi vaginal floraning xilma-xilligini ko'paytirishi mumkin. Maxsus proteobakteriya sifatida Pseudomonas rivojlanmagan homiladorlik holatlarida nomutanosib ravishda tez-tez topildi. Pseudomonas gram manfiy tayyoqcha bo'lib

opportunistic pathogen hisoblanadi va u qin florasining tarkibiy qismi hisoblanmaydi. *Pseudomonas* tananing har qanday qismida va har qanday to'qimalarda paydo bo'lishi mumkin, kuyish yoki yaralarda, o'rta quloqda, shox pardada, nafas olish yo'llarida va siydik chiqarish kanalida tez-tez uchraydi. Ushbu bakteriya endokardit, gastroenterit, empiema va hatto sepsisga ham sabab bo'lishi mumkin [38]. Mualliflar shunday xulosaga kelishdiki, vaginal floradagi nomutanosiblik qin orqali bachadonga o'tishi mumkin, bu yerda ular mahalliy immunitet reaksiyasini qo'zg'atishi va xemokinlarni faollashtirishi mumkin. Bu ishni buzishi mumkin. Bu o'z navbatida mahalliy immun tizimining mikrosirkulyatsiyasini buzilishiga va odatlangan homila tushishiga olib keladi [38].

Diagnostik tekshiruv

Qin mikrobiomi muvozanatining skriningi rivojlanmagan homiladorlik, odatlangan homila tushishi bilan kasallangan bemorlarda tashxis va davolashni sezilarli darajada yaxshilovchi yangi usul bo'lib xizmat qilishi mumkin[38]. Qin mikrobiomining tahlili mikroblarning to'liq spektrini va mos keladigan kichik guruhlarini aniqlash imkonini beradi. Avvalgi yondashuvdan farqli o'laroq, bu patogen mikroblarni yo'q qilish uchun antibiotik terapiyasida maqsadli bo'lish imkoniyatini va probiotiklarni qabul qilish fiziologik mikrob spektrini tiklash imkoniyatini yaratadi.

Davolashga zamonaviy yondashuv

Topilgan bakteriyalar spektriga va ularning kichik guruhlariga qarab, maqsadli va individual antibiotik davolash tavsiya qilish mumkin, agar kerak bo'lsa qo'shimcha tegishli probiotiklar ham beriladi. Shunday qilib, takroriy bakterial vaginoz xavfi kamayadi va "idiopatik bepustlik" bilan kasallangan juftliklar individual terapiya olishlari mumkin bo'ladi. Antibiotiklardan metronidazol, klindamitsin kabi bakterial vaginoz uchun vositalar qisqa muddatli yaxshilanishlarni ta'minlaydi [39,40]. Bundan tashqari, laktobakteriyalarning ko'payishini va pHni pasaytirish uchun estrogen, sut kislotasi yoki borik kislotasini qo'llash mumkin [39-41]. Ba'zi mualliflar antibiotiklar bilan davolashdan keyin vaginal mikrobiomni modulyatsiya qilish uchun yoki asosiy davolash sifatida probiotiklardan foydalanishni tavsiya qiladilar [42].

Xulosalar

Yuqorida keltirilgan ma'lumotlar jinsiy a'zolar (ayniqsa vaginal va endometrial) mikrobiom va ARTlarning muvaffaqiyati, reproduktiv natijalar o'rtasidagi bog'liqlikni ko'rsatadi. Disbiyoz, bakterial vaginoz yoki ba'zi *Lactobacilli* turlarining yo'qligi implantatsiyaning muvaffaqiyatsizligiga olib kelishi mumkin. Kompleks *Lactobacillus* shtammlarining o'zaro ta'siri sog'lom organizmlarning qin mikroflorasi muvozanatida muhim rol o'ynaydi. *Lactobacillus crispatus* esa tanani bakteriyalardan himoya qiladi, vaginoz va tug'ilishga ijobiy ta'sir ko'rsatadi.

Bundan tashqari, endometriy mikrobiotida laktobakteriyalar ustunlik qiladigan floraning yo'qligi ko'rinadi. Shunday qilib, qin mikrobiomining skriningi va disbalans yangi tadqiqot manbasiga aylanishi va samarali davolash usullarini taqdim etishi mumkin. Individual terapiya, shu jumladan antibiotiklar va/yoki probiotiklar yoki sut kislotalari preparatini qo'llash vaginal va endometrial mikrobiom disbiozini yaxshilash va ARTda homiladorlikning yuqori ko'rsatkichlariga, rivojlanmagan homiladorlikda yangi reabilitatsiya usullari

rivojlanishiga olib keladi. Shunga qaramay, klinik bayonnomalar yaratish va davolash tadqiqot usullarini mukammallashtirish uchun qo'shimcha tadqiqotlar talab qilinadi.

Adabiyotlar/Literatura/References:

1. Franasiak, J.M.; Scott, R.T., Jr. Reproductive tract microbiome in assisted reproductive technologies. *Fertil. Steril.* 2015, 104, 1364–1371. [CrossRef]
2. Gagliardi, A.; Totino, V.; Cacciotti, F.; Iebba, V.; Neroni, B.; Bonfiglio, G.; Schippa, S. Rebuilding the Gut Microbiota Ecosystem. *Int. J. Environ. Res. Public Health* 2018, 15, 1679. [CrossRef]
3. Garcia-Velasco, J.A.; Budding, D.; Campe, H.; Malfertheiner, S.F.; Hamamah, S.; Santjohanser, C.; Schuppe-Koistinen, I.; Nielsen, H.S.; Vieira-Silva, S.; Laven, J. The reproductive microbiome—Clinical practice recommendations for fertility specialists. *Reprod. Biomed. Online* 2020, 41, 443–453. [CrossRef]
4. Whipps, J.M.; Lewis, K.; Cooke, R.C. Mycoparasitism and plant disease control. In *Fungi in Biological Control Systems*; Burge, N.M., Ed.; Manchester University Press: Manchester, UK, 1988; p. 176.
5. Sirota, I.; Zarek, S.M.; Segars, J.H. Potential Influence of the Microbiome on Infertility and Assisted Reproductive Technology. *Semin. Reprod. Med.* 2014, 32, 35–42. [CrossRef]
6. Moreno, I.; Codoner, F.M.; Vilella, F.; Valbuena, D.; Martinez-Blanch, J.F.; Jimenez-Almazan, J.; Alonso, R.; Alama, P.; Remohi, J.; Pellicer, A. Evidence that the endometrial microbiota has an effect on implantation success or failure. *Am. J. Obstet. Gynecol.* 2016, 215, 684–703. [CrossRef]
7. Aragon, I.M.; Herrera-Imbroda, B.; Queipo-Ortuno, M.I.; Castillo, E.; del Moral, J.S.; Gomez-Millan, J.; Yucel, G.; Lara, M.F. The Urinary Tract Microbiome in Health and Disease. *Eur. Urol. Focus* 2018, 4, 128–138. [CrossRef]
8. Baker, J.M.; Chase, D.M.; Herbst-Kralovetz, M.M. Uterine Microbiota: Residents, Tourists, or Invaders? *Front. Immunol.* 2018, 9, 208. [CrossRef]
9. Moreno, I.; Franasiak, J.M. Endometrial microbiota—New player in town. *Fertil. Steril.* 2017, 108, 32–39. [CrossRef]
10. The Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project. *Nature* 2019, 569, 641–648. [CrossRef]
11. Moreno, I.; Simon, C. Deciphering the effect of reproductive tract microbiota on human reproduction. *Reprod. Med. Biol.* 2019, 18, 40–50. [CrossRef]
12. Hok, T.T.; Loen, L.K.; Tjia, N.T. Comparative bacteriology of the endocervical mucus. *Am. J. Obstet. Gynecol.* 1967, 98, 781–783. [CrossRef]
13. Vitale, S.G.; Loen, L.K.; Tjia, N.T. The Role of Genital Tract Microbiome in Fertility: A Systematic Review. *Int. J. Mol. Sci.* 2021, 23, 180. [CrossRef] [PubMed]
14. Wolf, E.A.; Rettig, H.C.; Lupatsch, M.; Schluter, B.; Schafer, K.; Friedrich, D.; Graspeuntner, S.; Rupp, J. Culturomics Approaches Expand the Diagnostic Accuracy for Sexually Transmitted Infections. *Int. J. Mol. Sci.* 2021, 22, 10815. [CrossRef] [PubMed]
15. Burton, J.P.; Reid, G. Evaluation of the Bacterial Vaginal Flora of 20 Postmenopausal Women by Direct (Nugent Score) and Molecular (Polymerase Chain Reaction and Denaturing Gradient Gel Electrophoresis) Techniques. *J. Infect. Dis.* 2002, 186, 1770–1780. [CrossRef]
16. Pavlova, S.I.; Kilic, A.O.; Kilic, S.S.; So, J.S.; Nader-Macias, M.E.; Simoes, J.A.; Tao, L. Genetic diversity of vaginal lactobacilli from women in different countries based on 16S rRNA gene sequences. *J. Appl. Microbiol.* 2002, 92, 451–459. [CrossRef] [PubMed]
17. Yarza, P.; Yilmaz, P.; Pruesse, E.; Glockner, F.O.; Ludwig, W.; Schleifer, K.H.; Whitman, W.B.; Euzéby, J.; Amann, R.; Rossello-Mora, R. Uniting the classification of cultured and uncultured bacteria and archaea using 16S rRNA gene sequences. *Nat. Rev. Microbiol.* 2014, 12, 635–645. [CrossRef]

18. Eckburg, P.B.; Bik, E.M.; Bernstein, C.N.; Purdom, E.; Dethlefsen, L.; Sargent, M.; Gill, S.R.; Nelson, K.E.; Relman, D.A. Diversity of the human intestinal microbial flora. *Science* 2005, 308, 1635–1638. [CrossRef]
19. Hyman, R.W.; Fukushima, M.; Diamond, L.; Kumm, J.; Giudice, L.C.; Davis, R.W. Microbes on the human vaginal epithelium. *Proc. Natl. Acad. Sci. USA* 2005, 102, 7952–7957. [CrossRef] [PubMed]
20. Kumar, J.; Kumar, M.; Gupta, S.; Ahmed, V.; Bhambi, M.; Pandey, R.; Chauhan, N.S. An Improved Methodology to Overcome Key Issues in Human Fecal Metagenomic DNA Extraction. *Genom. Proteom. Bioinform.* 2016, 14, 371–378. [CrossRef]
21. Dominguez-Bello, M.G.; Costello, E.K.; Contreras, M.; Magris, M.; Hidalgo, G.; Fierer, N.; Knight, R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc. Natl. Acad. Sci. USA* 2010, 107, 11971–11975. [CrossRef] [PubMed]
22. Holzer, P.; Farzi, A. Neuropeptides and the microbiota-gut-brain axis. *Adv. Exp. Med. Biol.* 2014, 817, 195–219.
23. Chang, P.V.; Hao, L.; Offermanns, S.; Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. *Proc. Natl. Acad. Sci. USA* 2014, 111, 2247–2252. [CrossRef] [PubMed]
24. Boskey, E.R.; Cone, R.A.; Whaley, K.J.; Moench, T.R. Origins of vaginal acidity: High D/L lactate ratio is consistent with bacteria being the primary source. *Hum. Reprod.* 2001, 16, 1809–1813. [CrossRef] [PubMed]
25. Garcia-Velasco, J.; Menabrito, M.; Catalán, I.B. What fertility specialists should know about the vaginal microbiome: A review. *Reprod. Biomed. Online* 2017, 35, 103–112. [CrossRef]
26. O’Hanlon, D.E.; Come, R.A.; Moench, T.R. Vaginal pH measured in vivo: Lactobacilli determine pH and lactic acid concentration. *BMC Microbiol.* 2019, 19, 13. [CrossRef] [PubMed]
27. Witkin, S.S.; Linhares, I.M. Why do lactobacilli dominate the human vaginal microbiota? *BJOG—Int. J. Obstet. Gynaecol.* 2017, 124, 606–611. [CrossRef] [PubMed]
28. O’Hanlon, D.E.; Moench, T.R.; A Cone, R. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. *BMC Infect. Dis.* 2011, 11, 200. [CrossRef]
29. Ravel, J.; Gajer, P.; Abdo, Z.; Schneider, G.M.; Koenig, S.S.; McCulle, S.L.; Karlebach, S.; Gorle, R.; Russell, J.; Tacket, C.O. Vaginal microbiome of reproductive-age women. *Proc. Natl. Acad. Sci. USA* 2011, 108 (Suppl. S1), 4680–4687. [CrossRef]
30. Zhou, X.; Brown, C.J.; Abdo, Z.; Davis, C.C.; Hansmann, M.A.; Joyce, P.; Foster, J.A.; Forney, L.J. Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women. *ISME J.* 2007, 1, 121–133. [CrossRef] [PubMed]
31. Gajer, P.; Brotman, R.M.; Bai, G.; Sakamoto, J.; Schutte, U.M.; Zhong, X.; Koenig, S.S.; Fu, L.; Ma, Z.S.; Zhou, X. Temporal dynamics of the human vaginal microbiota. *Sci. Transl. Med.* 2012, 4, 132ra52. [CrossRef] [PubMed]
32. Verhelst, R.; Verstraelen, H.; Claeys, G.; Verschraegen, G.; van Simaey, L.; de Ganck, C.; de Backer, E.; Temmerman, M.; Vanechoutte, M. Comparison between Gram stain and culture for the characterization of vaginal microflora: Definition of a distinct grade that resembles grade I microflora and revised categorization of grade I microflora. *BMC Microbiol.* 2005, 5, 61. [CrossRef] [PubMed]
33. Zheng, J.; Wittouck, S.; Salvetti, E.; Franz, C.; Harris, H.M.B.; Mattarelli, P.; O’Toole, P.W.; Pot, B.; Vandamme, P.; Walter, J. A taxonomic note on the genus *Lactobacillus*: Description of 23 novel genera, emended description of the genus *Lactobacillus* Beijerinck 1901, and union of *Lactobacillaceae* and *Leuconostocaceae*. *Int. J. Syst. Evol. Microbiol.* 2020, 70, 2782–2858. [CrossRef]

34. DiGiulio, D.B.; Callahan, B.J.; McMurdie, P.J.; Costello, E.K.; Lyell, D.J.; Robaczewska, A.; Sun, C.L.; Goltsman, D.S.; Wong, R.J.; Shaw, G.; et al. Temporal and spatial variation of the human microbiota during pregnancy. *Proc. Natl. Acad. Sci. USA* 2015, 112, 11060–11065. [CrossRef] [PubMed]
35. Jauniaux, E.; Farquharson, R.G.; Christiansen, O.B.; Exalto, N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. *Hum. Reprod.* 2006, 21, 2216–2222. [CrossRef] [PubMed]
36. WHO. WHO: Recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended 14 October 1976. *Acta Obstet. Gynecol. Scand.* 1977, 56, 247–253.
37. Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: A committee opinion. *Fertil. Steril.* 2020, 113, 533–535. [CrossRef] [PubMed]
38. Fan, T.; Zhong, X.M.; Wei, X.C.; Miao, Z.L.; Luo, S.Y.; Cheng, H.; Xiao, Q. The alteration and potential relationship of vaginal microbiota and chemokines for unexplained recurrent spontaneous abortion. *Medicine* 2020, 99, e23558. [CrossRef] [PubMed]
39. Deng, Z.L.; Gottschick, C.; Bhuju, S.; Masur, C.; Abels, C.; Wagner-Dobler, I. Metatranscriptome Analysis of the Vaginal Microbiota Reveals Potential Mechanisms for Protection against Metronidazole in Bacterial Vaginosis. *mSphere* 2018, 3, e00262-18. [CrossRef] [PubMed]
40. Gustin, A.T.; Thurman, A.R.; Chandra, N.; Schifanella, L.; Alcaide, M.; Fichorova, R.; Doncel, G.F.; Gale, M., Jr.; Klatt, N.R. Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis. *Am. J. Obstet. Gynecol.* 2022, 226, 225.e1–225.e15. [CrossRef]
41. Shen, J.; Song, N.; Williams, C.J.; Brown, C.J.; Yan, Z.; Xu, C.; Forney, L.J. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. *Sci. Rep.* 2016, 6, 24380. [CrossRef]
42. Plummer, E.L.; Bradshaw, C.S.; Doyle, M.; Fairley, C.K.; Murray, G.L.; Bateson, D.; Masson, L.; Slifirski, J.; Tachedjian, G.; Vodstrcil, L.A. Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review. *PLoS ONE* 2021, 16, e0246953. [CrossRef]
43. Reichman, O.; Akins, R.; Sobel, J.D. Boric Acid Addition to Suppressive Antimicrobial Therapy for Recurrent Bacterial Vaginosis. *Sex. Transm. Dis.* 2009, 36, 732–734. [CrossRef]
44. Bohbot, J.M.; Darai, E.; Bretelle, F.; Bami, G.; Daniel, C.; Cardot, J.M. Efficacy and safety of vaginally administered lyophilized *Lactobacillus crispatus* IP 174178 in the prevention of bacterial vaginosis recurrence. *J. Gynecol. Obstet. Hum. Reprod.* 2018, 47, 81–86. [CrossRef] [PubMed]

MEDICINEPROBLEMS.UZ- TIBBIYOT FANLARINING DOLZARB MASALALARI

№ 2 (3)-2025

TOPICAL ISSUES OF MEDICAL SCIENCES

**TIBBIYOT FANLARINING DOLZARB
MASALALARI** elektron jurnali
02.03.2023 yilda 132099-sonli guvohnoma
bilan davlat ro'yxatidan o'tkazilgan.
Muassis: "SCIENCEPROBLEMS TEAM"
mas'uliyati cheklangan jamiyati.

ТАҲРИРИЯТ МАНЗИЛИ:
Toshkent shahri, Yakkasaroy tumani,
Kichik Beshyog'och ko'chasi, 70/10-uy.
Elektron manzil:
scienceproblems.uz@gmail.com
Telegram kanal:
https://t.me/Scienceproblemsteam_uz